Two cases of burning mouth syndrome treated with olanzapine.
Two case reports of patients suffering from burning mouth syndrome (BMS), a type of somatoform disorder, who were treated with olanzapine are discussed. One case was a 54-year-old female with BMS who failed to respond to milnacipran treatment. Olanzapine (2.5 mg/day) brought about dramatic improvement in the patient's symptoms, and thereafter milnacipran withdrawal further eliminated her symptoms. The second case was a 51-year-old male with BMS who failed to respond to paroxetine treatment. Olanzapine (2.5 mg/day) was added to the treatment regimen and increased to 5.0 mg/day the following week. The patient noted a reduction in symptoms and continued to live normally thereafter without experiencing severe symptoms. These findings suggest that olanzapine may be useful in the treatment of BMS.
Ueda
Nobuhisa
N
Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Japan. nueda@med.uoeh-u.ac.jp
Kodama
Yuki
Y
Hori
Hikaru
H
Umene
Wakako
W
Sugita
Atsuko
A
Nakano
Hideki
H
Yoshimura
Reiji
R
Nakamura
Jun
J
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D002054:Burning Mouth Syndrome / Q000188:drug therapy* / Q000523:psychology; D003521:Cyclopropanes / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D000077152:Olanzapine; D017374:Paroxetine / Q000627:therapeutic use; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003521:Cyclopropanes; D001569:Benzodiazepines; D017374:Paroxetine; D000078764:Milnacipran; D000077152:Olanzapine